Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться

Boehringer Ingelheim

Специалисты компании

Личные визитки людей, которые сами указали это место работы и разрешили показ здесь. Имена из реестров мы не берём.

Пока никто не показал здесь свою визитку.

Работаете здесь? Покажите свою визитку: фото, должность, кнопка «Написать». Почту и телефон не показываем. Только с вашего разрешения, убрать можно в любой момент. Я здесь работаю — показать мою визитку

Нашли ошибку или чужую визитку? Сообщить модератору

4
исследования идут сейчас
84
исследования в базе
79
Россия
5
Казахстан · идут 4

Разрешения по годам

Новые препаратыБиоэквивалентность

Фазы

Фаза I 2
Фаза II 12
Фаза II–III 1
Фаза III 48
Фаза IV 9
Завершено Фаза III Россия
Nintedanib · Boehringer Ingelheim

An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Санкт-Петербург 1 центр 752 участника во всех странах ClinicalTrials.gov 1199.33
Завершено Фаза IV Россия
Telmisartan; Valsartan · Boehringer Ingelheim

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study

Москва, Санкт-Петербург 9 центров 885 участников во всех странах ClinicalTrials.gov 502.396
Завершено Россия
Spiolto® Respimat® · Boehringer Ingelheim

Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto®Respimat® in Routine Clinical Practice

Москва, Санкт-Петербург и ещё 48 городов 116 центров 4 819 участников во всех странах ClinicalTrials.gov 1237-0072
Завершено Фаза III Россия
tiotropium 5mcg/day; placebo · Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma

453 участника во всех странах ClinicalTrials.gov 205.417
Завершено Фаза III Россия
Olodaterol (BI 1744); Olodaterol (BI 1744); Placebo; Olodaterol (BI1744); Olodaterol (BI 1744) placebo · Boehringer Ingelheim

Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease.

157 участников во всех странах ClinicalTrials.gov 1222.38
Завершено Фаза IV Россия
Telmisartan; Combination of Telmisartan and Ramipril; Ramipril · Boehringer Ingelheim

ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.

31 546 участников во всех странах ClinicalTrials.gov 502.373
Завершено Фаза III Россия
Tiotropium Inhalation Solution · Boehringer Ingelheim

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

983 участника во всех странах ClinicalTrials.gov 205.254
Завершено Фаза III Россия
dabigatran dose 1; dabigatran dose 2 · Boehringer Ingelheim

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

5 897 участников во всех странах ClinicalTrials.gov 1160.71
Завершено Фаза III Россия
placebo plus docetaxel; BIBF 1120 plus docetaxel · Boehringer Ingelheim

Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Москва, Санкт-Петербург и ещё 10 городов 15 центров 1 314 участников во всех странах ClinicalTrials.gov 1199.13
Завершено Фаза IV Россия
Telmisartan; Telmisartan; Hydrochlorothiazide · Boehringer Ingelheim

A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)

894 участника во всех странах ClinicalTrials.gov 502.550
Завершено Фаза II Россия
BI 10773; placebo; metformin · Boehringer Ingelheim

A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control

408 участников во всех странах ClinicalTrials.gov 1245.9
Завершено Фаза II Россия
BIBF 1120; BIBF 1120; BIBF 1120; BIBF 1120 · Boehringer Ingelheim

A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Москва, Санкт-Петербург 2 центра 198 участников во всех странах ClinicalTrials.gov 1199.35
Завершено Россия
1160.129 · Boehringer Ingelheim

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)

Москва, Санкт-Петербург и ещё 19 городов 24 центра 37 235 участников во всех странах ClinicalTrials.gov 1160.129
Завершено Фаза III Россия
BI 1356; BI 1356 + metformin; Bi 1356 + metformin; Metformin; metformin; matching placebo · Boehringer Ingelheim

A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control

857 участников во всех странах ClinicalTrials.gov 1218.46
Завершено Фаза III Россия
Olodaterol (BI 1744); Olodaterol (BI 1744); Formoterol; Placebo · Boehringer Ingelheim

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

937 участников во всех странах ClinicalTrials.gov 1222.14
Завершено Фаза IV Россия
tiotropium inhalation; salmeterol xinafoate; fluticasone propionate; placebo matched for fluticasone propionate · Boehringer Ingelheim

A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

2 488 участников во всех странах ClinicalTrials.gov 352.2046
Завершено Фаза II Россия
tamsulosin hydrochloride · Boehringer Ingelheim

An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges.

143 участника во всех странах ClinicalTrials.gov 527.66

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.